TNFRSF9 and chronic obstructive pulmonary disease: Blocking co-stimulation through CD137 resulted in a modest but significant reduction in these cytotoxic/pro-inflammatory molecules compared with MP alone, hence a more targeted approach with blocking anti-CD137 may prove more efficacious in treating patients with COPD where the use of corticosteroids has no proven disease modifying effect [2].